Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD

NCT ID: NCT00680966

Last Updated: 2014-03-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2013-06-30

Brief Summary

The purpose of this study is to determine whether it is more effective to treat adolescents, with diagnoses of both depression and substance use disorder, with a treatment addressing the substance use first and then treating the depression or to first treat the depression and then treat the substance use or whether treating both disorders simultaneously is most effective.

It is expected that treatment of both disorders at the same time will be the most effective.

Detailed Description

Comorbidity is a well established aspect of adolescent psychopathology. The majority of adolescents entering treatment have more than one condition. This study will evaluate service delivery methods of integrating empirically supported interventions for depression and non-nicotine substance use disorders (SUD)in an effort to improve treatment engagement, response, and maintenance of gains. The two examined interventions are the Adolescent Coping With Depression course (ACWD) and Functional Family Therapy (FFT).

This study will expand upon previous research by systematically treating both depression and SUD. Over a 5 year period, 180 adolescents with depression/SUD and their parents/guardians will be recruited in Oregon and New Mexico and randomly assigned to 1 of 3 conditions: (a) FFT followed by ACWD, (b) ACWD followed by FFT, or (c) an intervention combining and augmenting FFT and ACWD (Integrated Treatment). Each treatment arm will consist of 24 sessions provided over 20 weeks. Participants will be assessed at intake, after the provision of 6, 12 (Mid-treatment), 18 and 24 (Post-treatment)treatment sessions, and at 6 and 12 month follow-ups.

Conditions

Adolescent; Depression; Substance Use Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TX1

Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)

Group Type: EXPERIMENTAL

Adolescent Coping With Depression/Functional Family Therapy

Intervention Type: BEHAVIORAL

ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents

TX 2

ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)

Group Type: EXPERIMENTAL

Adolescent Coping With Depression/Functional Family Therapy

Intervention Type: BEHAVIORAL

ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents

TX 3

Combination of an augmented FFT and ACWD - Integrated treatment

Group Type: EXPERIMENTAL

Adolescent Coping With Depression/Functional Family Therapy

Intervention Type: BEHAVIORAL

ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents

Interventions

Adolescent Coping With Depression/Functional Family Therapy

ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents

Intervention Type: BEHAVIORAL

Other Intervention Names

FFT; ACWD

Eligibility Criteria

Inclusion Criteria

1. DSM-IV-TR diagnosis of depression, defined as MDD, dysthymia, or substance-induced mood disorder meeting MDD or dysthymia symptom criteria

2. DSM-IV-TR diagnosis of one or more non-nicotine SUD

3. Some reported illicit drug use in the last 90 days

4. 13-17 years of age

5. parent or guardian willing to participate in study

6. basic English competency (ability to converse in English)

Exclusion Criteria

1. Current and acute suicidal ideation at the level warranting inpatient treatment

2. current psychotic symptoms

3. the adolescent's sibling is already participating in the study

4. if on psychiatric medications, a significant change in dosage levels in the prior 4 weeks -

• Minimum Eligible Age: 13 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oregon Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul D Rohde, Ph. D.

Role: PRINCIPAL_INVESTIGATOR

Oregon Research Institute

Locations

Oregon Research Institute

Eugene, Oregon, United States

Countries

United States

Other Identifiers

1R01DA021357

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DA021357

Identifier Type: -

Identifier Source: org_study_id